1. A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis. Issue 10 (12th September 2017) Authors: Weinblatt, Michael E.; Bingham, Clifton O.; Burmester, Gerd‐Rüdiger; Bykerk, Vivian P.; Furst, Daniel E.; Mariette, Xavier; van der Heijde, Désirée; van Vollenhoven, Ronald; VanLunen, Brenda; Ecoffet, Cécile; Cioffi, Christopher; Emery, Paul Journal: Arthritis & rheumatology Issue: Volume 69:Issue 10(2017) Page Start: 1937 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. AB0738 DUAL NEUTRALISATION OF INTERLEUKIN (IL)–17A AND IL–17F WITH BIMEKIZUMAB IN MODERATE-TO-SEVERE PLAQUE PSORIASIS: 60-WEEK RESULTS FROM A RANDOMISED, DOUBLE-BLINDED, PHASE 2B EXTENSION STUDY. (June 2019) Authors: Blauvelt, Andrew; Papp, Kim a.; Merola, Joseph F.; Gottlieb, Alice B.; Cross, Nancy; Madden, Cynthia; Wang, Maggie; Cioffi, Christopher; Griffiths, Christopher E.M. Journal: Annals of the rheumatic diseases Issue: Volume 78(2019)Supplement 2 Page Start: 1834 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. Issue 10273 (6th February 2021) Authors: Gordon, Kenneth B; Foley, Peter; Krueger, James G; Pinter, Andreas; Reich, Kristian; Vender, Ronald; Vanvoorden, Veerle; Madden, Cynthia; White, Katy; Cioffi, Christopher; Blauvelt, Andrew Journal: Lancet Issue: Volume 397:Issue 10273(2021) Page Start: 475 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. Issue 10273 (6th February 2021) Authors: Reich, Kristian; Papp, Kim A; Blauvelt, Andrew; Langley, Richard G; Armstrong, April; Warren, Richard B; Gordon, Kenneth B; Merola, Joseph F; Okubo, Yukari; Madden, Cynthia; Wang, Maggie; Cioffi, Christopher; Vanvoorden, Veerle; Lebwohl, Mark Journal: Lancet Issue: Volume 397:Issue 10273(2021) Page Start: 487 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study. Issue 10061 (3rd December 2016) Authors: Smolen, Josef S; Burmester, Gerd-Rüdiger; Combe, Bernard; Curtis, Jeffrey R; Hall, Stephen; Haraoui, Boulos; van Vollenhoven, Ronald; Cioffi, Christopher; Ecoffet, Cécile; Gervitz, Leon; Ionescu, Lucian; Peterson, Luke; Fleischmann, Roy Journal: Lancet Issue: Volume 388:Issue 10061(2016) Page Start: 2763 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗